Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors September 2, 2022
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights August 12, 2022
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights May 11, 2022
Neuro player Jazz Pharmaceuticals Dives into Immuno-Oncology, Inking Cytokine Pact with Werewolf April 8, 2022
Werewolf Therapeutics and Jazz Pharmaceuticals Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule April 8, 2022
